PD-1 and PD-L1 Immunotherapy Market - Global Outlook and Forecast 2022-2028

March 2022 | 69 pages | ID: P6C4C134230FEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of PD-1 and PD-L1 Immunotherapy in Global, including the following market information:

Global PD-1 and PD-L1 Immunotherapy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global PD-1 and PD-L1 Immunotherapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

PD-1 inhibitor Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of PD-1 and PD-L1 Immunotherapy include AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck, Pfizer, Roche, Novartis, Jiangsu HengRui Medicine and Innovent, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the PD-1 and PD-L1 Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global PD-1 and PD-L1 Immunotherapy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global PD-1 and PD-L1 Immunotherapy Market Segment Percentages, by Type, 2021 (%)

• PD-1 inhibitor
• PD-L1 inhibitor

Global PD-1 and PD-L1 Immunotherapy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global PD-1 and PD-L1 Immunotherapy Market Segment Percentages, by Application, 2021 (%)

• Solid Tumors
• Blood-related Tumors

Global PD-1 and PD-L1 Immunotherapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global PD-1 and PD-L1 Immunotherapy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies PD-1 and PD-L1 Immunotherapy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies PD-1 and PD-L1 Immunotherapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AstraZeneca
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Merck
• Pfizer
• Roche
• Novartis
• Jiangsu HengRui Medicine
• Innovent
• Eli Lilly
• GlaxoSmithKline

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 PD-1 and PD-L1 Immunotherapy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global PD-1 and PD-L1 Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL PD-1 AND PD-L1 IMMUNOTHERAPY OVERALL MARKET SIZE

2.1 Global PD-1 and PD-L1 Immunotherapy Market Size: 2021 VS 2028
2.2 Global PD-1 and PD-L1 Immunotherapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top PD-1 and PD-L1 Immunotherapy Players in Global Market
3.2 Top Global PD-1 and PD-L1 Immunotherapy Companies Ranked by Revenue
3.3 Global PD-1 and PD-L1 Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 PD-1 and PD-L1 Immunotherapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies PD-1 and PD-L1 Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 PD-1 and PD-L1 Immunotherapy Players in Global Market
  3.6.1 List of Global Tier 1 PD-1 and PD-L1 Immunotherapy Companies
  3.6.2 List of Global Tier 2 and Tier 3 PD-1 and PD-L1 Immunotherapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global PD-1 and PD-L1 Immunotherapy Market Size Markets, 2021 & 2028
  4.1.2 PD-1 inhibitor
  4.1.3 PD-L1 inhibitor
4.2 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
  4.2.1 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue, 2017-2022
  4.2.2 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue, 2023-2028
  4.2.3 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global PD-1 and PD-L1 Immunotherapy Market Size, 2021 & 2028
  5.1.2 Solid Tumors
  5.1.3 Blood-related Tumors
5.2 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
  5.2.1 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue, 2017-2022
  5.2.2 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue, 2023-2028
  5.2.3 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global PD-1 and PD-L1 Immunotherapy Market Size, 2021 & 2028
6.2 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
  6.2.1 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue, 2017-2022
  6.2.2 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue, 2023-2028
  6.2.3 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028
  6.3.2 US PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.3.3 Canada PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.3.4 Mexico PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028
  6.4.2 Germany PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.4.3 France PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.4.4 U.K. PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.4.5 Italy PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.4.6 Russia PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.4.7 Nordic Countries PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.4.8 Benelux PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028
  6.5.2 China PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.5.3 Japan PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.5.4 South Korea PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.5.5 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.5.6 India PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028
  6.6.2 Brazil PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.6.3 Argentina PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028
  6.7.2 Turkey PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.7.3 Israel PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.7.4 Saudi Arabia PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
  6.7.5 UAE PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AstraZeneca
  7.1.1 AstraZeneca Corporate Summary
  7.1.2 AstraZeneca Business Overview
  7.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Major Product Offerings
  7.1.4 AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
  7.1.5 AstraZeneca Key News
7.2 Bristol-Myers Squibb
  7.2.1 Bristol-Myers Squibb Corporate Summary
  7.2.2 Bristol-Myers Squibb Business Overview
  7.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Major Product Offerings
  7.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
  7.2.5 Bristol-Myers Squibb Key News
7.3 F. Hoffmann-La Roche
  7.3.1 F. Hoffmann-La Roche Corporate Summary
  7.3.2 F. Hoffmann-La Roche Business Overview
  7.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Major Product Offerings
  7.3.4 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
  7.3.5 F. Hoffmann-La Roche Key News
7.4 Merck
  7.4.1 Merck Corporate Summary
  7.4.2 Merck Business Overview
  7.4.3 Merck PD-1 and PD-L1 Immunotherapy Major Product Offerings
  7.4.4 Merck PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
  7.4.5 Merck Key News
7.5 Pfizer
  7.5.1 Pfizer Corporate Summary
  7.5.2 Pfizer Business Overview
  7.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Major Product Offerings
  7.5.4 Pfizer PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
  7.5.5 Pfizer Key News
7.6 Roche
  7.6.1 Roche Corporate Summary
  7.6.2 Roche Business Overview
  7.6.3 Roche PD-1 and PD-L1 Immunotherapy Major Product Offerings
  7.6.4 Roche PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
  7.6.5 Roche Key News
7.7 Novartis
  7.7.1 Novartis Corporate Summary
  7.7.2 Novartis Business Overview
  7.7.3 Novartis PD-1 and PD-L1 Immunotherapy Major Product Offerings
  7.7.4 Novartis PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
  7.7.5 Novartis Key News
7.8 Jiangsu HengRui Medicine
  7.8.1 Jiangsu HengRui Medicine Corporate Summary
  7.8.2 Jiangsu HengRui Medicine Business Overview
  7.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Major Product Offerings
  7.8.4 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
  7.8.5 Jiangsu HengRui Medicine Key News
7.9 Innovent
  7.9.1 Innovent Corporate Summary
  7.9.2 Innovent Business Overview
  7.9.3 Innovent PD-1 and PD-L1 Immunotherapy Major Product Offerings
  7.9.4 Innovent PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
  7.9.5 Innovent Key News
7.10 Eli Lilly
  7.10.1 Eli Lilly Corporate Summary
  7.10.2 Eli Lilly Business Overview
  7.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Major Product Offerings
  7.10.4 Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
  7.10.5 Eli Lilly Key News
7.11 GlaxoSmithKline
  7.11.1 GlaxoSmithKline Corporate Summary
  7.11.2 GlaxoSmithKline Business Overview
  7.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Major Product Offerings
  7.11.4 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
  7.11.5 GlaxoSmithKline Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. PD-1 and PD-L1 Immunotherapy Market Opportunities & Trends in Global Market
Table 2. PD-1 and PD-L1 Immunotherapy Market Drivers in Global Market
Table 3. PD-1 and PD-L1 Immunotherapy Market Restraints in Global Market
Table 4. Key Players of PD-1 and PD-L1 Immunotherapy in Global Market
Table 5. Top PD-1 and PD-L1 Immunotherapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global PD-1 and PD-L1 Immunotherapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies PD-1 and PD-L1 Immunotherapy Product Type
Table 9. List of Global Tier 1 PD-1 and PD-L1 Immunotherapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 PD-1 and PD-L1 Immunotherapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 30. AstraZeneca Corporate Summary
Table 31. AstraZeneca PD-1 and PD-L1 Immunotherapy Product Offerings
Table 32. AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 33. Bristol-Myers Squibb Corporate Summary
Table 34. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product Offerings
Table 35. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 36. F. Hoffmann-La Roche Corporate Summary
Table 37. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product Offerings
Table 38. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 39. Merck Corporate Summary
Table 40. Merck PD-1 and PD-L1 Immunotherapy Product Offerings
Table 41. Merck PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 42. Pfizer Corporate Summary
Table 43. Pfizer PD-1 and PD-L1 Immunotherapy Product Offerings
Table 44. Pfizer PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 45. Roche Corporate Summary
Table 46. Roche PD-1 and PD-L1 Immunotherapy Product Offerings
Table 47. Roche PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 48. Novartis Corporate Summary
Table 49. Novartis PD-1 and PD-L1 Immunotherapy Product Offerings
Table 50. Novartis PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 51. Jiangsu HengRui Medicine Corporate Summary
Table 52. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product Offerings
Table 53. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 54. Innovent Corporate Summary
Table 55. Innovent PD-1 and PD-L1 Immunotherapy Product Offerings
Table 56. Innovent PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 57. Eli Lilly Corporate Summary
Table 58. Eli Lilly PD-1 and PD-L1 Immunotherapy Product Offerings
Table 59. Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 60. GlaxoSmithKline Corporate Summary
Table 61. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product Offerings
Table 62. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. PD-1 and PD-L1 Immunotherapy Segment by Type in 2021
Figure 2. PD-1 and PD-L1 Immunotherapy Segment by Application in 2021
Figure 3. Global PD-1 and PD-L1 Immunotherapy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global PD-1 and PD-L1 Immunotherapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by PD-1 and PD-L1 Immunotherapy Revenue in 2021
Figure 8. By Type - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 12. US PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 16. Germany PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 17. France PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 24. China PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 28. India PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 30. Brazil PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 33. Turkey PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 37. AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Merck PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Pfizer PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Roche PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Innovent PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)